ID: ALA535831

Max Phase: Preclinical

Molecular Formula: C25H27ClN4O3

Molecular Weight: 430.51

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1ccc(NCC(=O)c2ccccc2)c(O)c1CC(=O)NCc1ccc(C(=N)N)cc1.Cl

Standard InChI:  InChI=1S/C25H26N4O3.ClH/c1-16-7-12-21(28-15-22(30)18-5-3-2-4-6-18)24(32)20(16)13-23(31)29-14-17-8-10-19(11-9-17)25(26)27;/h2-12,28,32H,13-15H2,1H3,(H3,26,27)(H,29,31);1H

Standard InChI Key:  RMZJOKTVTSYCSD-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 430.51

Molecular Weight (Monoisotopic): 430.2005

AlogP: 3.14

#Rotatable Bonds: 9

Polar Surface Area: 128.30

Molecular Species: BASE

HBA: 5

HBD: 5

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 10.08

CX Basic pKa: 11.50

CX LogP: 2.06

CX LogD: 0.26

Aromatic Rings: 3

Heavy Atoms: 32

QED Weighted: 0.15

Np Likeness Score: -0.71

References

1. Hanessian S, Therrien E, van Otterlo WA, Bayrakdarian M, Nilsson I, Fjellström O, Xue Y..  (2006)  Phenolic P2/P3 core motif as thrombin inhibitors--design, synthesis, and X-ray co-crystal structure.,  16  (4): [PMID:16290930] [10.1016/j.bmcl.2005.10.082]

Source

Source(1):

• Scientific Literature